| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	HC Wainwright & Co. analyst Matthew Keller downgrades Sensei Biotherapeutics (NASDAQ:SNSE) from Buy to Neutral.
																	
																	Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of ...
																	
																	
																	Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of ...